Loading
Everything done to a potential drug before it is given to a human: lab experiments, animal testing, and the safety and manufacturing work regulators require. Most candidates never make it out.
Preclinical development establishes that a drug hits its target, kills or slows tumours in cells and animals, can be made consistently, and is safe enough at the planned dose to test in people; toxicology in two species is normally required before the first human trial. 'Preclinical evidence' on this site means a claim supported only by such work, and the reader should discount it heavily: roughly 90% of drugs that enter human testing fail, and preclinical findings often do not reproduce even in other labs. Better models (organoids, humanised mice, patient-derived xenografts) and more rigorous reporting are attempts to shrink the gap between bench and bedside.
Showing the technology this term belongs to: Patient-derived xenografts.
The clearest recent statement of where the evidence stands: promising in a dish, untested in people, and already causing harm through self-dosing.
This is the scientific basis for pairing ivermectin with checkpoint antibodies in the Cedars-Sinai and ICONIC trials. Its key figure is now in doubt, which makes those trials more important, not less, as the only way to find out whether the effect is real.
Useful as a map of the laboratory story; it contains no patient outcomes.
This is the paper the online claims usually trace back to. It is a call for trials, not evidence that the drug works in people, and the trials it called for are still running.
Shares The multitargeted drug ivermectin: from an antiparasitic agent to a repositioned cancer drug, Ivermectin in cancer treatment: should healthcare providers caution or explore its therapeutic potential?, Fenbendazole (veterinary anthelmintic), Mebendazole.
Shares Medical oncology, Oncology research, Phase 1, 2 and 3 trials.
Shares Ivermectin, a potential anticancer drug derived from an antiparasitic drug, The multitargeted drug ivermectin: from an antiparasitic agent to a repositioned cancer drug, Mebendazole, Ivermectin.
Shares Ivermectin in cancer treatment: should healthcare providers caution or explore its therapeutic potential?, Fenbendazole (veterinary anthelmintic), Mebendazole, Ivermectin.
Shares Fenbendazole (veterinary anthelmintic), Mebendazole, Ivermectin.
Shares Cancer reports, Cancer biology & therapy, JNCI cancer spectrum, Medical oncology.
Shares Patient-derived xenografts, CRISPR functional genomics, Patient-derived organoids.
Shares Organoid, Patient-derived organoids.